Y Intercept Hong Kong Ltd Takes $2.18 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Y Intercept Hong Kong Ltd purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 6,170 shares of the biotechnology company’s stock, valued at approximately $2,177,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the third quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB raised its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of United Therapeutics during the 3rd quarter worth $111,000. 94.08% of the stock is owned by institutional investors.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 114,164 shares of company stock valued at $41,671,293. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Down 0.8 %

NASDAQ:UTHR opened at $358.21 on Tuesday. The business’s 50-day simple moving average is $362.39 and its two-hundred day simple moving average is $360.91. The stock has a market cap of $15.99 billion, a PE ratio of 15.73, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82.

Analyst Ratings Changes

A number of equities analysts recently commented on UTHR shares. HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.